Education
About Us
Working with TipRanks
Follow Us
vTv Therapeutics (VTVT)
NASDAQ:VTVT
VTVT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.62 - $26.99
Previous CloseN/A
Volume611.00
Average Volume (3M)2.61K
Market Cap
$67.18M
Enterprise Value$72.61M
Total Cash (Recent Filing)$25.92M
Total Debt (Recent Filing)$79.00K
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 06, 2025EPS Estimate
-0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding2,617,215
10 Day Avg. Volume3,515
30 Day Avg. Volume2,607
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue4.27K
Enterprise Value/Gross Profit-1.86K
Enterprise Value/Ebitda-3.05
Forecast
1Y Price Target
$36.00Price Target Upside71.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe swift activation of trial sites for the CATT1 trial is viewed favorably as it will likely increase the cadence of patient enrollment.
Regulatory AdvancementsThe FDA granted cadi Breakthrough Therapy Designation, highlighting its potential to offer a substantial improvement over existing therapies.
Therapeutic EfficacyCadisegliatin has demonstrated promising therapeutic benefits in managing type 1 diabetes, including a significant reduction in symptomatic hypoglycemic episodes and an absence of ketoacidosis in the Phase 2 SimpliciT1 study.
Bears Say
Clinical Trial DurationThe re-initiation of the CATT1 Phase 3 trial with an updated protocol that reduces the trial duration and provides continuous glucose monitors to patients will accelerate the timeline for larger pivotal studies.
vTv Therapeutics News
VTVT FAQ
What was vTv Therapeutics’s price range in the past 12 months?
vTv Therapeutics lowest stock price was $12.62 and its highest was $26.99 in the past 12 months.
What is vTv Therapeutics’s market cap?
vTv Therapeutics’s market cap is $67.18M.
When is vTv Therapeutics’s upcoming earnings report date?
vTv Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 48 days.
How were vTv Therapeutics’s earnings last quarter?
vTv Therapeutics released its earnings results on Aug 12, 2025. The company reported -$0.92 earnings per share for the quarter, missing the consensus estimate of -$0.825 by -$0.095.
Is vTv Therapeutics overvalued?
According to Wall Street analysts vTv Therapeutics’s price is currently Undervalued.
Does vTv Therapeutics pay dividends?
vTv Therapeutics does not currently pay dividends.
What is vTv Therapeutics’s EPS estimate?
vTv Therapeutics’s EPS estimate is -0.98.
How many shares outstanding does vTv Therapeutics have?
vTv Therapeutics has 2,617,215 shares outstanding.
What happened to vTv Therapeutics’s price movement after its last earnings report?
vTv Therapeutics reported an EPS of -$0.92 in its last earnings report, missing expectations of -$0.825. Following the earnings report the stock price went down -6.335%.
Which hedge fund is a major shareholder of vTv Therapeutics?
Currently, no hedge funds are holding shares in VTVT
vTv Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.00 (71.18% Upside)
$36.00 (71.18% Upside)
Crowd Wisdom
Negative
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.86%
12-Months-Change
Fundamentals
Return on Equity
-203.31%
Trailing 12-Months
Asset Growth
-43.07%
Trailing 12-Months
Company Description
vTv Therapeutics
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
VTVT Stock 12 Month Forecast
Average Price Target
$36.00
▲(71.18% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Clearside Biomedical
―
Jasper Therapeutics
―
Inozyme Pharma
―
Biomea Fusion
―
Ownership Overview
21.19% Insiders
8.88% Mutual Funds
11.99% Other Institutional Investors
56.28% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---